NEW YORK (Reuters) – The Lancet medical journal on Tuesday said “serious scientific questions” had been brought to its attention about the validity of the data behind a widely-cited study on the dangers of the use of the anti-malarial drug hydroxychloroquine in hospitalized patients with COVID-19.
The Lancet study published on May 22 found that the anti-malarial drug hydroxychloroquine, which U.S. President Donald Trump took and has urged others to use, was tied to an increased risk of death in hospitalized COVID-19 patients. Several clinical trials were put on hold after the study was published.
(Reporting by Michael Erman, Editing by Franklin Paul)
